Ziprasidone Mesylate 20 mg/mL
- Product NDC
- 72485-430
- Requested package NDC
- 72485-430-10
- 11-digit product format
- 724850430
- Labeler code
- 72485
- Product ID
- 72485-430_aae33647-bd18-4cbb-b264-bb8e17ad91c2
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Ziprasidone Mesylate
- Dosage form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAMUSCULAR
- Labeler
- Armas Pharmaceuticals Inc.
- Application
- ANDA217595
- Marketing category
- ANDA
- Marketing start
- 2026-09-21
- Substance
- ZIPRASIDONE MESYLATE
- Active strength
- 20 mg/mL
- Pharmacologic classes
- Atypical Antipsychotic [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A217595-001 | ZIPRASIDONE MESYLATE | ZIPRASIDONE MESYLATE | EQ 20MG BASE/VIAL | POWDER / INTRAMUSCULAR | AP | 2025-09-03 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A217595-001 | AP |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A217595-001 | ZIPRASIDONE MESYLATE | EQ 20MG BASE/VIAL | POWDER / INTRAMUSCULAR | AP | 2025-09-03 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A217595-001 | ZIPRASIDONE MESYLATE | EQ 20MG BASE/VIAL | POWDER / INTRAMUSCULAR | AP | 2025-09-03 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A217595-001 | ZIPRASIDONE MESYLATE | EQ 20MG BASE/VIAL | POWDER / INTRAMUSCULAR | AP | 2025-09-03 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A217595-001 | ZIPRASIDONE MESYLATE | EQ 20MG BASE/VIAL | POWDER / INTRAMUSCULAR | AP | 2025-09-03 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A217595-001 | ZIPRASIDONE MESYLATE | EQ 20MG BASE/VIAL | POWDER / INTRAMUSCULAR | AP | 2025-09-03 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217595-001 | ZIPRASIDONE MESYLATE | EQ 20MG BASE/VIAL | POWDER / INTRAMUSCULAR | AP | 2025-09-03 | 31067a03dcf5… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A217595-001 | ZIPRASIDONE MESYLATE | EQ 20MG BASE/VIAL | POWDER / INTRAMUSCULAR | AP | 2025-09-03 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A217595-001 | AP | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A217595-001 | AP | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A217595-001 | AP | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A217595-001 | AP | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A217595-001 | AP | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217595-001 | AP | 1 | 31067a03dcf5… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A217595-001 | AP | 1 | a50c72e98297… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Ziprasidone Mesylate 20 mg/mL
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| ZIPRASIDONE MESYLATE | 20 mg/mL |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 3X6SAX83JZ | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 351223 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| c5c27f0f-4e45-4bca-bb9a-2d3f1c243348 | Available on FDA.report |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Ziprasidone Mesylate 20 mg/mL | ZIPRASIDONE MESYLATE | Armas Pharmaceuticals Inc. | c5c27f0f-4e45-4bca-bb9a-2d3f1c243348 | 2026-09-18 | Boxed warning, Warnings, Adverse reactions | 217595 ANDA217595 72485-430-10 72485-430 72485043010 |
| Ziprasidone Mesylate | ZIPRASIDONE MESYLATE | STERISCIENCE SPECIALTIES PRIVATE LIMITED | 1ffd16c3-25ac-4839-9ea9-4efd32926b95 | 2025-09-16 | Boxed warning, Warnings, Adverse reactions | 217595 ANDA217595 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 72485-430-10 | 72485043010 | 10 VIAL, SINGLE-DOSE in 1 CARTON (72485-430-10) / 1 mL in 1 VIAL, SINGLE-DOSE (72485-430-01) | 2026-09-21 | No | No | Current |